Zürich17°Clear
Filtered by Topic
Latest Pharmaceuticals news and updates from Switzerland. AI-curated articles covering Pharmaceuticals topics.
← Show All NewsSwitzerland
An industry-backed study warns that changes in US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040 through weaker growth and possible relocation of production. The article should clearly distinguish the study’s scenarios from established forecasts and examine the stakes for jobs, exports and patients.
5 days ago · 1 source
Business
The Australian pharmaceutical group CSL Behring has completed a transformation process at its Bern site, resulting in a reduction of its workforce by just under 10%. The company stated the move strengthens its long-term competitiveness.
SWI swissinfo.ch
Healthcare
A new report revealing that drug discounts are not being passed on to consumers has sparked political outrage, highlighting a system where Swiss patients struggle to access innovative medicines.
The Local Switzerland · +2 more
Business
Pharmaceutical giant Sandoz has signed a multi-million-dollar agreement with Shanghai Henlius Biotech to develop and commercialize up to ten biosimilars, significantly expanding its footprint in the generic biologics market.
SWI swissinfo.ch
Business
While Basel's world-beating pharmaceutical hub adapts to a new global order, major Swiss firms like Roche and Novartis are aggressively expanding their footprint in the United States, particularly North Carolina, signaling a strategic shift to secure future growth.
SWI swissinfo.ch · +1 more
Sandoz
Basel-based pharmaceutical firm Sandoz has agreed to a settlement of nearly $480 million in a long-running US antitrust lawsuit. The case, involving 43 states, alleged unlawful price-fixing in the generics market, though Sandoz does not admit guilt in the settlement.
SWI swissinfo.ch
Business
Swiss pharmaceutical firm Sandoz has received marketing authorization in Brazil for a generic version of the popular GLP-1 drug semaglutide. The move marks a significant expansion for the Basel-based company into the lucrative $1.8 billion Brazilian market for diabetes treatments.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis has announced the acquisition of British start-up Myricx Bio for an initial $1.1 billion, a strategic move to bolster its portfolio of antibody-drug conjugates for treating various solid tumours.
SWI swissinfo.ch
Business
A look at major developments in Switzerland's corporate world. The SNB confirms UBS's crisis resilience as the bank plans a US expansion, Roche announces a successful trial for a new lung cancer drug, and retailer Migros opens its first 24-hour automated supermarket.
SWI swissinfo.ch · +3 more
Business
Severin Schwan, Chairman of Swiss pharmaceutical giant Roche, has heavily criticized the protectionist policies of the United States and China at the Swiss Economic Forum, stating they are disrupting the company's structures and comparing US tariff strategies to 'blackmail'.
SWI swissinfo.ch
Business
Swiss generics giant Sandoz is escalating a trade dispute, preparing a complaint to the European Commission against what it calls heavily subsidised, low-priced penicillin imports from China that distort competition and create strategic health vulnerabilities.
SWI swissinfo.ch
Business
As part of a broader M&A spending spree, Swiss pharmaceutical giant Novartis is set to acquire US biotech firm Avidity Biosciences for approximately $12 billion. The deal is aimed at strengthening Novartis's neuroscience business and is one of the largest transactions in a record-breaking year for Swiss M&A.
SWI swissinfo.ch
Economy
Switzerland's industrial sector saw production fall sharply by 7.1% in the first quarter of 2026 compared to the previous year. The decline was driven by a substantial 20.4% contraction in the crucial pharmaceutical industry, signaling economic headwinds for the country.
SWI swissinfo.ch
Health
Switzerland's drug regulator, Swissmedic, is closely monitoring the drug Tavneos after its Japanese distributor warned doctors against new prescriptions following 20 deaths since 2021. US and European agencies are also reviewing the drug's approval amid safety concerns.
SWI swissinfo.ch
Economy
According to a new EY study, Switzerland's largest companies invested heavily in innovation in 2025, achieving the world's third-highest research intensity rate, driven primarily by the pharmaceutical sector.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Roche has announced an agreement to acquire PathAI, a US-based artificial intelligence specialist, for $750 million. The acquisition aims to bolster Roche's position in AI-driven diagnostics and accelerate the development of personalized medicine.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis is strengthening its US manufacturing footprint with a new facility in North Carolina. The plant will produce active ingredients for both solid medications and advanced RNA-based therapies as part of a multi-billion dollar investment plan.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis has reported a decline in Q1 turnover, attributing the pressure to the loss of patent protection on billion-euro drugs like Entresto. The company is bracing for a significant impact from copycat drugs throughout the year.
SWI swissinfo.ch
Business
Swiss pharmaceutical firm Roche announced first-quarter sales of CHF 14.7 billion, a 5% decrease in its reporting currency due to the strong franc. However, the company highlighted a 6% increase at constant exchange rates, driven by its Pharmaceuticals Division, which met analyst targets.
SWI swissinfo.ch
Health
The conflict disrupting the Strait of Hormuz has renewed concerns over Switzerland's fragile pharmaceutical supply chains, a vulnerability exposed during the Covid-19 pandemic. The Federal Office for National Economic Supply confirms that essential medicines remain the primary category at risk of shortages.
SWI swissinfo.ch
